The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index; 4 of the 46 sources its claims cite were checked for support.
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis
Open accessAbstract
BACKGROUND: Behavioural, cognitive, and pharmacological interventions can all be effective for insomnia. However, because of inadequate resources, medications are more frequently used worldwide. We aimed to estimate the comparative effectiveness of pharmacological treatments for the acute and long-term treatment of adults with insomnia disorder. METHODS: In this systematic review and network meta-analysis, we searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, PsycINFO, WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and websites of regulatory agencies from database inception to Nov 25, 2021, to identify published and unpublished randomised controlled trials. We included studies comparing pharmacological treatments or placebo as monotherapy for the treatment of adults (≥18 year) with insomnia disorder. We assessed the certainty of evidence using the confidence in network meta-analysis (CINeMA) framework. Primary outcomes were efficacy (ie, quality of sleep measured by any self-rated scale), treatment discontinuation for any reason and due to side-effects specifically, and safety (ie, number of patients with at least one adverse event) both for acute and long-term treatment. We estimated summary standardised mean differences (SMDs) and odds ratios (ORs) using pairwise and network meta-analysis with random effects. This study is registered with Open Science Framework, https://doi.org/10.17605/OSF.IO/PU4QJ. FINDINGS: We included 170 trials (36 interventions and 47 950 participants) in the systematic review and 154 double-blind, randomised controlled trials (30 interventions and 44 089 participants) were eligible for the network meta-analysis. In terms of acute treatment, benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more efficacious than placebo (SMD range: 0·36-0·83 [CINeMA estimates of certainty: high to moderate]). Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0·27-0·71 [moderate to very low]). Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to any cause than ramelteon (OR 0·72 [95% CI 0·52-0·99; moderate], 0·70 [0·51-0·95; moderate] and 0·71 [0·52-0·98; moderate], respectively). Zopiclone and zolpidem caused more dropouts due to adverse events than did placebo (zopiclone: OR 2·00 [95% CI 1·28-3·13; very low]; zolpidem: 1·79 [1·25-2·50; moderate]); and zopiclone caused more dropouts than did eszopiclone (OR 1·82 [95% CI 1·01-3·33; low]), daridorexant (3·45 [1·41-8·33; low), and suvorexant (3·13 [1·47-6·67; low]). For the number of individuals with side-effects at study endpoint, benzodiazepines, eszopiclone, zolpidem, and zopiclone were worse than placebo, doxepin, seltorexant, and zaleplon (OR range 1·27-2·78 [high to very low]). For long-term treatment, eszopiclone and lemborexant were more effective than placebo (eszopiclone: SMD 0·63 [95% CI 0·36-0·90; very low]; lemborexant: 0·41 [0·04-0·78; very low]) and eszopiclone was more effective than ramelteon (0.63 [0·16-1·10; very low]) and zolpidem (0·60 [0·00-1·20; very low]). Compared with ramelteon, eszopiclone and zolpidem had a lower rate of all-cause discontinuations (eszopiclone: OR 0·43 [95% CI 0·20-0·93; very low]; zolpidem: 0·43 [0·19-0·95; very low]); however, zolpidem was associated with a higher number of dropouts due to side-effects than placebo (OR 2·00 [95% CI 1·11-3·70; very low]). INTERPRETATION: Overall, eszopiclone and lemborexant had a favorable profile, but eszopiclone might cause substantial adverse events and safety data on lemborexant were inconclusive. Doxepin, seltorexant, and zaleplon were well tolerated, but data on efficacy and other important outcomes were scarce and do not allow firm conclusions. Many licensed drugs (including benzodiazepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available. Melatonin, ramelteon, and non-licensed drugs did not show overall material benefits. These results should serve evidence-based clinical practice. FUNDING: UK National Institute for Health Research Oxford Health Biomedical Research Centre.
Overview
CoChat Summary
## TL;DR
This systematic review and network meta-analysis included 170 RCTs (47,950 participants) of 36 pharmacological treatments for adults with insomnia disorder, with 154 double-blind RCTs (44,089 participants) eligible for the network meta-analysis. Overall, eszopiclone and lemborexant had the most favorable profiles, while benzodiazepines were effective short term but had less favorable tolerability and safety, and long-term evidence was sparse.
## Key findings
- The review included 170 trials (36 interventions, 47,950 participants); 154 double-blind RCTs (30 interventions, 44,089 participants) were eligible for network meta-analysis.
- In acute treatment, benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more efficacious than placebo, with SMDs 0.36–0.83 and high to moderate certainty.
- In acute treatment, intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer all-cause discontinuations than ramelteon: OR 0.72, 0.70, and 0.71, respectively.
- In long-term treatment, eszopiclone and lemborexant were more efficacious than placebo (SMD 0.63 and 0.41), and eszopiclone and zolpidem had fewer all-cause discontinuations than ramelteon (OR 0.43 for both).
- Zopiclone and zolpidem caused more dropouts due to adverse events than placebo in acute treatment (OR 2.00 and 1.79), and zopiclone also had more adverse-event dropouts than eszopiclone (OR 1.82), daridorexant (3.45), and suvorexant (3.13).
## Methods
- Systematic review and network meta-analysis of randomized controlled trials comparing pharmacological treatments or placebo as oral monotherapy for adults (≥18 years) with insomnia disorder; double-blind RCTs were used for the network meta-analysis.
- Searched Cochrane CENTRAL, MEDLINE, PubMed, Embase, PsycINFO, WHO ICTRP, ClinicalTrials.gov, and regulatory-agency websites from database inception to Nov 25, 2021, with no language restrictions.
- Primary outcomes were efficacy (self-rated sleep quality/satisfaction), acceptability (all-cause discontinuation), tolerability (discontinuation due to adverse events), and safety (any adverse event); analyses used random-effects pairwise and network meta-analysis, with certainty assessed using CINeMA.
## Limitations
- The paper states that many comparisons were rated low or very low quality by CINeMA, especially at long-term timepoints, and that many trials did not report adequate information on randomisation and allocation concealment.
- The authors state that long-term networks were mostly single-standing nodes connected only to placebo, so many active-treatment comparisons relied on indirect evidence and the untestable consistency assumption.
- The paper states that it included only double-blind trials to improve rigor; evidence also suggests a limitation that specific adverse events were reported inconsistently, and there was very little long-term evidence for many drugs.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 1 Not valid · 29 Not checked · 145 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Current treatment guidelines have conflicting recommendations, 11-14 and the findings from our study differ from those of a systematic review and network meta-analysis about hypnotics for insomnia in older adults, 37 which included 24 studies (5917 patients) and listed doxepin, zaleplon, and suvorexant among the best options.”
What the sources say
- Supportedcites [11] Sateia, 2017, Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline, J Clin Sleep Med source
The 'Clinical Guidelines and Practice Parameters' section of the AASM 2017 guideline is a survey of the then-current guidelines and records that they diverge: the 2008 AASM parameter recommended short/intermediate-acting BZDs, BzRAs or ramelteon as first-line pharmacotherapy and the 2005 NIH consensus supported benzodiazepine agonists, while the 2016 ACP guideline made no specific recommendations for single agents and judged the evidence for benzodiazepines, trazodone and melatonin insufficient; the British Association for Psychopharmacology statement recommended prolonged-release melatonin as first-line for those over 55, whereas this guideline suggests clinicians not use melatonin. The same section also notes 'preliminary but conflicting evidence' for valerian and first-generation H1 antagonists, and 'Clinical Application' records the AGS Beers criteria recommending avoidance of benzodiazepines in older patients. Our copy thus clearly treats the topic of mutually discordant guideline recommendations, supporting the broad background claim even though it does not use the phrase 'conflicting recommendations'. (LLM, conf=0.82)
- Not checked yetcites [12] Riemann, 2017, European guideline for the diagnosis and treatment of insomnia, J Sleep Res source
- Not checked yetcites [13] Wilt, 2016, Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians, Ann Intern Med source
- Not checked yetcites [14] Wilson, 2010, British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders, J Psychopharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“eszopiclone was more effective than ramelteon (0.63 [0·16-1·10; very low]) and zolpidem (0·60 [0·00-1·20; very low]).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 154 double-blind, randomised controlled trials correspond to 30 interventions.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to any cause than ramelteon (OR 0·72 [95% CI 0·52-0·99; moderate], 0·70 [0·51-0·95; moderate] and 0·71 [0·52-0·98; moderate], respectively).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“zopiclone caused more dropouts than did eszopiclone (OR 1·82 [95% CI 1·01-3·33; low]), daridorexant (3·45 [1·41-8·33; low), and suvorexant (3·13 [1·47-6·67; low]).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
89 more claims
Create a free account to see all 178 claims and to verify the 42 references still open.
- Probably not a substantial claim. 50
- The quote only partly states this claim. 4
- It may state two separate claims as one. 44
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence 3 9 38 suggests that pharmacodynamic factors—such as selectivity for specific GABA A receptor subunits—and pharmacokinetic parameters—such as half-life and absorption rate—play a crucial role in determining the risk of dependence, withdrawal, and adverse effects associated with these agents.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“Further, melatonin and other OTC medications were not considered effective according to this analysis.”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as De Crescenzo et al., 2022
In the citing paper
“Recently a meta-analysis was published in the Lancet , comparing all pharmacological treatments for insomnia with each other (De Crescenzo et al., 2022).”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as De Crescenzo et al., 2022
Citations
Cites
International Classification of Sleep Disorders-Third Edition
Sateia, M. J. (2014) · Chest · doi:10.1378/chest.14-0970 · Cited by 3,860
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Self-citationBaglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., Lombardo, C., & Riemann, D. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.01.011 · Cited by 2,779
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Ranking treatments in frequentist network meta-analysis works without resampling methods
Rücker, G., & Schwarzer, G. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0060-8 · Cited by 1,732
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationSateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Research works printed but not linked: 1
- Jaffer, 2017, Trazodone for insomnia: a systematic review, Innov Clin Neurosci, 14, 24
Cited by
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
“The Recently a meta-analysis was published in the Lancet , comparing all pharmacological treatments for insomnia with each other (De Crescenzo et al., 2022).”
BackgroundMorin, C. M., & Buysse, D. J. (2024) · New England Journal of Medicine · doi:10.1056/nejmcp2305655 · Cited by 181
Yue, J.-L., Chang, X.-W., Zheng, J.-W., Shi, L., Xiang, Y., Que, J., Yuan, K., Teng, T., Teng, T., Li, Y., et al. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101746 · Cited by 132
Long-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 115
Ma, T., Wang, Z., Qin, X. S., Ju, C., Lau, W. C. Y., Man, K. K. C., Castle, D. J., Chang, W. C., Chan, A. Y. L., Cheung, E. C. L., et al. (2023) · SLEEP · doi:10.1093/sleep/zsad124 · Cited by 77
“…review and meta-analysis reported that adverse events were similar with eszopiclone, zopiclone and zolpidem, compared with BZDs; in contrast, zaleplon seems to have a more benign profile 10 . r As an alternative to BZDs, Z-drugs were once considered to have a better safety profile than the BZDs 9 .”
Metadata
- Authors
- De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., Del Giovane, C., Quested, D. J., Cowen, P. J., Barbui, C., Amato, L., Efthimiou, O., & Cipriani, A.
- Affiliations
- Oxford Health NHS Foundation Trust (GB)
- University of Rome Tor Vergata (IT)
- Soseikai General Hospital (JP)
- Regione Lazio (IT)
- Magna Graecia University (IT)
- University of Verona (IT)
- University of Bern (CH)
- Corresponding author
- Cipriani, Andrea
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 400
- Issue
- 10347
- Pages
- 170-184
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4285498627
- Cited by
- 446
- References
- 42
- Citations by year
- 2026: 94 · 2025: 138 · 2024: 111 · 2023: 86 · 2022: 17
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Open Access CRIS of the University of Bern
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (80083)
- NIHR Oxford Biomedical Research Centre (BRC-1215\u201320005)
- National Institute for Health and Care Research (RP-2017-08-ST2\u2013006, RCPG 0407-10155-RISC)
- Angelini Pharma
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
- Keywords
- insomnia, pharmacotherapy, benzodiazepines, eszopiclone, zolpidem, zopiclone, melatonin, ramelteon, zaleplon, doxylamine, lemborexant, treatment discontinuation, adverse events, sleep quality, long-term treatment, acute treatment, comparative effectiveness, adults
- MeSH terms
- Eszopiclone, Zolpidem, Adult, Benzodiazepines, Doxepin, Humans, Sleep Initiation and Maintenance Disorders, Melatonin, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00878-9
- The paper
- De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., Del Giovane, C., Quested, D. J., Cowen, P. J., Barbui, C., Amato, L., Efthimiou, O., & Cipriani, A. (2022). Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(22)00878-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.